Just days before presenting at ASH conference, Syndax outlines plan to raise $150M
Syndax is banking that upcoming clinical data will be enough to woo investors — to the tune of $150 million.
The biotech kept it short in its announcement Tuesday afternoon, saying it is planning to sell $150 million worth of shares of its stock via a public offering. While no date or exact number of shares was given for the offering, the biotech noted it will be giving underwriters 30 days to purchase up to an additional 15% of shares sold in the public offering.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.